(Q31131772)

English

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data (English)

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

author name string

UK HARP-III Collaborative Group

1

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

language of work or name

0 references

publication date

1 December 2017

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

Nephrology Dialysis Transplantation

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

32

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

12

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

2043-2051

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

copyright license

Creative Commons Attribution 4.0 International

14 March 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

CKD Prevalence Varies across the European General Population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Angiotensin-neprilysin inhibition versus enalapril in heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

A predictive model for progression of chronic kidney disease to kidney failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Association of left atrial volume with mortality among ESRD patients with left ventricular hypertrophy referred for kidney transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Irbesartan in patients with heart failure and preserved ejection fraction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Prevalence of chronic kidney disease in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Comparison of treatment effects between animal experiments and clinical trials: systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Cyclic GMP transporters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Where is the evidence that animal research benefits humans?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Statistics notes: Analysing controlled trials with baseline and follow up measurements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Regulation of filtration rate by glomerular mesangial cells in health and diabetic renal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

The natriuretic-peptide family

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Estimating the effect of the run-in on the power of the Physicians' Health Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

21 June 2018

Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFW321

21 January 2018

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFW321

21 January 2018

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFW321

21 January 2018

A simple sample size formula for analysis of covariance in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFW321

21 January 2018

Combined angiotensin inhibition for the treatment of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFW321

21 January 2018

Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFW321

21 January 2018

Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFW321

21 January 2018

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFW321

21 January 2018

Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837485

25 November 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFW321

21 January 2018

Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/27646835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sacubitril/Valsartan (Entresto) for Heart Failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/27646835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and echocardiographic disease in patients starting end-stage renal disease therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27646835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

1 reference

https://pubmed.ncbi.nlm.nih.gov/27646835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/27646835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/NDT/GFW321

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5837485

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31131772&oldid=1850671230"